Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22523898 | 0.85 | NPC1 (0.45) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL2772033 | 0.80 | KMT2A (0.44) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL2771385 | 0.80 | MEN1 (0.46) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL4327363 | 0.79 | KMT2A (0.74) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL2773703 | 0.76 | MEN1 (0.56) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL2251549 | 0.75 | SCN9A (0.49) | — | |
| SCHEMBL3028344 | 0.75 | GRM5 (0.50) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL2771743 | 0.75 | RAB9A (0.49) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL21021758 | 0.74 | ADORA3 (0.44) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL22728512 | 0.73 | GRM5 (0.64) | NPC1RAB9AMEN1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185810-A1 | Novel Process for the Preparation of Filgotinib and Intermediates Thereof | UNICHEM LABORATORIES LIMITED (IN) | 2022-06-16 | — | — | US | disclosed |
| CN-110204542-B | Synthetic method of JAK1 inhibitor Filgotinib | 四川伊诺达博医药科技有限公司 | 2022-05-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185810-A1 | Novel Process for the Preparation of Filgotinib and Intermediates Thereof | ABL1, JAK1, JAK3 | NPC1 2673/4885RAB9A 471/4885MEN1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.